Information for Clinics

We understand that in the current situation colonoscopy testing has been restricted and access to laboratory calprotectin testing may be more difficult.

Since the BSG has recommended that only emergency colonoscopies are performed, we have collated some guidance to assist Clinicians on how to manage their symptomatic patients.

Advice from the BSG

NEW – BSG IBD Section and IBD Clinical Research Group position statement on SARS-CoV2 Vaccination:BSG

Read the Advice on Vaccination

Advice regarding working in endoscopy for vulnerable clinical staff during the COVID-19 pandemic:

Read the Guidance

COVID-19 Related Publications

New Publication - Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period

Patients with colonic IBD who have recently started therapy using agents such as biologics, JAK inhibitors, or azathioprine, should undergo endoscopy to assess the efficacy of treatment after 6–12 months. However, other tools could be used (eg, faecal calprotectin or bowel ultrasound). As such, endoscopic monitoring may not be essential.

A further risk is missed detection of early post-operative recurrence in patients with Crohn’s disease after ileocolonic surgery. Ileocolonoscopy to check the anastomosis site should be performed within 6–12 months after the surgery. Indirect tools, such as faecal calprotectin, bowel ultrasound, and magnetic resonance enterography, have been shown to be useful in disease monitoring and may help avoid endoscopy.

Click Here to Find Out More
Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience

The IBDoc® is a simple tool to use and high satisfaction is found among IBDoc® users. IBD patients should be adequately informed and trained on the use of this test. FC home tests are an additional value for e-health approach in IBD patients. In the near future, these tests could allow not only tight monitoring of IBD patients but also their greater involvement in disease management.

Click Here to Find Out More
A multi-centre prospective study of COVID-19 transmission following outpatient Gastrointestinal Endoscopy in the United Kingdom

When a COVID-minimised pathway is in place, patients (including those in a high risk “shielding” category) can now be reassured that concerns over COVID-19 infection should not stop them attending for GI endoscopy.

Click Here to Find Out More
BSG expanded consensus advice for the management of IBD during the COVID-19 pandemic

The BSG has given their expanded consensus advice for the management of IBD during the COVID-19 pandemic:

Click Here to Find Out More
Innovation in IBD Care During the COVID-19 Pandemic: Results of a Global Telemedicine Survey

This survey shows the changes in how IBD clinics have been operating before and during the COVID pandemic and what is anticipated moving forward.

Click Here to Find Out More
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic

A UK online survey of 125 hospitals shows that key tools for monitoring and managing IBD patients were removed or restricted due the current COVID 19 situation.

Click Here to Find Out More
Implications of recurrent SARS-CoV-2 outbreaks for IBD management

This publications states that the ability to detect deteriorations in disease and react remotely will be important:

  • IBD Apps for recording symptoms
  • Faecal calprotectin should be incorporated into remote monitoring, ideally using home kits for sample acquisition
Click Here to Find Out More
Faecal Calprotectin Indicates Intestinal Inflammation in COVID-19

This pilot study explores a relation between GI symptoms, intestinal inflammation (determined by FC) and faecal SARS-CoV-2-RNA in hospitalised patients with COVID-19.

Click Here to Find Out More

IBDoc® – Remote Management of Your IBD Patients

Using smartphone technology the IBDoc enables your UC and CD patients to test their own calprotectin levels in the comfort and safety of their own homes freeing up valuable resource at this challenging time.

The IBDoc generates a quantitative result between 30 – 1000µg/g which is quickly and securely transmitted to the clinic for immediate access by the clinical teams enabling you to continue to monitor your patients giving a good indication on the health of the gut.

Click Here to Visit the IBDoc® Page to Find Out More

IBDoc® Tutorial Videos for Healthcare Professionals

The videos below from BÜHLMANN have been made to assist healthcare professionals with the IBDoc® system:

Clinical Registration

Follow this short video to learn how to create a new IBDoc® clinic. A clinic will allow you and your colleagues to use IBDoc® for your patients.

How to Create a Clinical User

Learn how to set-up a new account for a Clinical User. The new user will then be able to use the IBDoc® account to manage patients.

Manage the Clinic

Once the Clinic and Clinical Users accounts are created, learn how to make changes to the accounts by following this short tutorial.

How to Create a Patient

Watch this tutorial to learn the different possibilities when creating a patient account. Patient basic settings can be modified to better satisfy your needs.

Resetting a Password

If patients lose their password, follow this video to see how to easily reset their password.

How to Review Results

The main purpose of IBDoc® is to generate faecal calprotectin data for your patient. Learn the different ways of consulting those results with this video.

BÜHLMANN Quantum Blue® – Rapid, Individual Calprotectin Testing

BÜHLMANN calprotectin assays offer a range of testing options, including Quantum Blue® individual lateral flow tests for those urgent requests.

Although traditionally the Quantum Blue is a valuable tool for rapid testing in clinic, in the current COVID-19 situation this is probably best performed in the laboratory for the following reasons:

  • Front line staff don’t have the capacity to perform additional tests at the moment
  • It has been documented that the virus is shed in stool, so samples are best handled in the controlled environment of the laboratory

Quantum Blue can give you quantitative faecal calprotectin results in just 4 easy steps and can also easily be linked directly to your computer for quick data input, making it an ideal choice in an emergency situation.

There are two assay ranges available:

LF-CHR25 100 – 1800µg/g
LF-CALE25 30 – 1000µg/g

Each pack contains 25 individually sealed tests – therefore if you only want one test, then you only have to use one.

Quantum Blue® has a well documented correlation to clinical outcome:

“This rapid bedside test can facilitate clinical decisions on hospital admission, such as deciding whether the IBD treatment should be intensified. Similarly, in the ambulatory setting, it is crucial when determining whether a patient should undergo endoscopy or not.”

Moniuszko et al. Polish Archives of Internal Medicine 2017. Rapid fecal calprotectin test for prediction of mucosal inflammation in ulcerative colitis and Crohn’s disease: A prospective cohort study.

“Quantum Blue® provides high diagnostic accuracy and was less time consuming in clinical routine than quantification of faecal calprotectin by ELISA. This makes the test an excellent candidate for the use in clinical routine.”

Schulz et al. Clinical Laboratory 2016.

Click Here to Visit the Quantum Blue® Page to Find Out More